Rare Cannabinoid Products
Nature’s Twin – Bioidentical Cannabinoids for Your Health and Wellness Products
The BayMedica biosynthetic production method is designed to deliver natural cannabinoids that are identical to those found in hemp and cannabis. We have produced more than 20 natural cannabinoids using various manufacturing technologies. Unlike “extracted” cannabinoids, BayMedica cannabinoids are made and purified by a proprietary process that is the same each and every time. Our Prodiol® cannabinoids are available as bulk raw ingredients for use in the health and wellness industry. Our cannabinoids can be combined in precise ratios to produce Defined SpectrumTM formulations with so-called, synergistic, entourage effects.
Move over CBD – Rare cannabinoids are the next big thing.
Beyond THC and CBD, there are more than a hundred rare cannabinoids that have unique characteristics that may have different physiological effects. Research suggests that these rare, minor cannabinoids may have more beneficial effects than THC and CBD for certain applications. Until now, you couldn’t readily obtain these rare, minor cannabinoids because of their extremely low levels in the cannabis plant, making them impractical and expensive to extract and separate from unwanted components like THC. We have pioneered the application of pharmaceutical methods like chemical synthesis and biosynthesis to produce these valuable minor cannabinoids.
We know cannabinoids in depth
Call us cannabinoid nerds. Our team of scientists have a depth of experience in cannabinoid biosynthesis, chemical synthesis and enzymatic biotransformation. We have been able to produce the rare cannabinoids CBDV, CBC and CBT at commercial scale and are now bringing additional cannabinoids like ∆9-THCV to large scale production.
Purity and quality you can trust
While many scientists may be able to reproduce a cannabinoid in the lab, very few can take it to large scale production. We can and we have. We produce rare, minor cannabinoids with the consistent high quality and purity needed for the health and wellness industry. Our cannabinoids are made via “pharmaceutical-grade” techniques, are lab tested, and third-party certified. We aim to be your preferred supplier of rare cannabinoid raw ingredients for your health and wellness products. Our cannabinoids can be combined in precise ratios to produce Defined Spectrum™ formulations with putative synergistic, so-called, “entourage” or “potentiation” effects.
We don’t touch the plant
Our method is environmentally sustainable, free of pesticides, fertilizers, mold and heavy metals using pharmaceutical bioreactors.
How to order BayMedica ProDiol™ rare, minor cannabinoids
Interested in purchasing wholesale CBDV, CBC or CBT for your health and wellness products? Or interested in advance orders of THCV? You can initiate an order by emailing [email protected].
Prodiol® Cannabinoids
Cannabichromene
Cannabichromene (CBC) is non-intoxicating, non-psychoactive cannabinoid that is believed to function by binding the CB2 receptor as well as the vanilloid receptor 1 (TRPV1) and transient receptor potential ankyrin 1 (TRPA1). The result of engaging these receptors is increased levels of natural endocannabinoids that are known to have positive effects on many body systems.
Cannabicitran
Cannabicitran (CBT) is one of the estimated 140+ rare cannabinoids found in the cannabis plant and is recognized as a non-intoxicating cannabinoid. CBT was discovered and isolated from Lebanese Cannabis sativa in 1974.
Cannabidivarin
Cannabidivarin (CBDV), is a non-psychoactive compound found in C. sativa, but unlike cannabidiol (CBD), CBDV is produced in very small amounts in hemp. CBDV has been shown to act through binding of various receptors including the ankryin-type receptor TRPA1 and vanilloid-type, TRPV1 and TRPV2 receptors. Like other CB2 agonists, CBDV is believed to produce a number of positive effects by engaging the endocannabinoid system.
Tetrahydrocannabivarin
Tetrahydrocannabivarin (THCV) is a minor cannabinoid and recognized as non-intoxicating. THCV has been shown to act as an antagonist of CB1 receptors of the endocannabinoid system as well as other endogenous receptors including GPR55 and TRPV1. THCV has been the subject of much clinical and nonclinical research into its physiological effects.
